Last reviewed · How we verify
GnRH antagonist
At a glance
| Generic name | GnRH antagonist |
|---|---|
| Also known as | Cetrotide®, orgalutran, cetrotide, Antagon, cetrorelix |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Menopausal Hormones and Sympathetic Activation (PHASE4)
- Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. (PHASE4)
- Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (NA)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study) (NA)
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (PHASE3)
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRH antagonist CI brief — competitive landscape report
- GnRH antagonist updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI